NOVO-B.CO Novo Nordisk A/S
Company Analysis
Latest News
Novo Nordisk Launches Wegovy Pill in Germany, Marking First EU Entry
Novo Nordisk launched the oral version of its Wegovy weight-loss drug in Germany on September 1, 2026. This release marks the first entry of the GLP-1 pill...
Eli Lilly wins FDA heart approval for Mounjaro, intensifying Novo Nordisk rivalry
The FDA approved Eli Lilly’s Mounjaro to reduce risks of heart attack, stroke, and cardiovascular death in high-risk adults with type 2 diabetes. This decision...
Novo Nordisk Shares Sink on Deutsche Bank Downgrade, Citing Wegovy Growth Risks
Deutsche Bank downgraded Novo Nordisk to sell from hold. The bank lowered its price target for the stock to DKK 265. Analysts cited concerns regarding a...
Novo Nordisk Shares Sink, Berenberg Cites Eli Lilly Obesity Rivalry
Novo Nordisk shares fell 3.4% on Wednesday. Berenberg Bank downgraded the stock from "buy" to "hold" and lowered its price target. Analysts cited intensifying...
Novo Nordisk launches Awiqli, reducing weekly insulin injections from seven to one
Novo Nordisk launched Awiqli (insulin icodec-abae) nationwide in the United States. This product is the first once-weekly basal insulin available for adults...
Novo Nordisk partners with AWS to accelerate drug discovery via London hub
Novo Nordisk and Amazon Web Services (AWS) have established a strategic partnership to accelerate drug discovery using artificial intelligence and cloud...
🟢 Novo Nordisk is trading 4.24% up today, rebounding after recent selling
Novo Nordisk is trading at DKK 306.05, up +4.24%, rebounding after recent selling tied to investor questions about Wegovy pill sales, pipeline prospects and...
🔴 Novo Nordisk drops 4.4% as Q2 earnings disappoint with Wegovy pill sales miss and CagriSema trial setback amid Eli Lilly rivalry
• Novo Nordisk shares fell 4.4% following its Q2 2026 earnings report, which included a narrow sales miss for its oral Wegovy pill. • Investors expressed...
Novo Nordisk's Obesity Drug Strategy Under Scrutiny Amid Eli Lilly Rivalry
Novo Nordisk is facing intensified focus on its rivalry with Eli Lilly in the obesity drug market, according to analysis from August 3, 2026. Investor...
Novo Nordisk Shares Sink 10%, Ziltivekimab Fails Large Phase 3 Trial
Novo Nordisk shares fell more than 10% after its experimental drug, ziltivekimab, failed the Phase 3 ZEUS trial. The study involved over 6,300 patients with...
🔴 Novo Nordisk is trading 10.5% down today on a soft 2026 outlook and slowing obesity drug growth
Novo Nordisk is trading 10.5% down at DKK 296.25 after investors reacted negatively to a softer-than-expected 2026 outlook and slower projected growth in...
Novo Nordisk sues Eli Lilly, alleging deceptive Zepbound and Mounjaro ads
Novo Nordisk filed a lawsuit against Eli Lilly in New Jersey federal court for alleged false and misleading advertising of GLP-1 drugs. The complaint targets...
Novo Nordisk to launch Extensior, countering unregulated semaglutide in South Africa
Novo Nordisk will launch Extensior in South Africa on July 27, 2026. This authorized version of Ozempic contains the same active ingredient, semaglutide. The...
Novo Nordisk’s Wegovy Secures Indian Approval, First GLP-1 for Liver Disease
The Central Drugs Standard Control Organisation (CDSCO) approved Novo Nordisk’s Wegovy to treat a severe form of fatty liver disease in India. The approval...
Novo Nordisk Wins EU Approval for Wegovy Pill, First Oral Treatment
Novo Nordisk secured marketing authorization from the European Commission for a once-daily pill version of Wegovy. This is the first oral GLP-1 receptor...
🟢 Novo Nordisk is trading 3.1% up today as shares rebound from a selloff over 2026 guidance
Novo Nordisk is trading 3.1% up at DKK 329.75 as shares stage a modest rebound from recent weakness tied to disappointing 2026 guidance and obesity drug...
Novo Nordisk reports zero bleeds for denecimig, strengthening FDA application
Novo Nordisk presented long-term data for its investigational hemophilia A treatment, denecimig (Mim8), at the ISTH 2026 Congress. Interim results from the...
Novo Nordisk Tests Vivani’s Semaglutide Implant, Targeting Chronic Weight Management
Novo Nordisk entered an agreement with Vivani Medical to evaluate the NPM-139 semaglutide implant. The collaboration utilizes Vivani’s NanoPortal technology...
🟢 NOVO-B.CO is trading 2.2% up today as Medicare Wegovy pilot improves demand outlook
NOVO-B.CO is trading 2.2% up at $324.30 as investors react to stronger U.S. access prospects for Wegovy following a new Medicare pilot program. • The pilot...
Novo Nordisk Wegovy enters Medicare pilot, slashing monthly costs to $50
Medicare launched a temporary 18-month pilot program to cover GLP-1 weight-loss drugs for the first time. The initiative provides millions of seniors and...